Keenova Publishes Real-World Data on Plantar Fibromatosis Treatment Patterns
Event summary
- Keenova published a peer-reviewed manuscript on real-world treatment patterns for plantar fibromatosis in The Journal of Foot and Ankle Surgery on February 16, 2026.
- The study found that most patients receive conservative treatments, with surgery being infrequent but often followed by continued conservative treatments, suggesting disease recurrence or persistent symptoms.
- Keenova is evaluating collagenase clostridium histolyticum (CCH) as a potential nonsurgical therapy in a Phase 3 clinical trial, though CCH is not currently approved for treating plantar fibromatosis.
The big picture
Keenova's publication highlights the unmet need for effective nonsurgical treatments for plantar fibromatosis, a rare condition with no FDA-approved therapies. The company's Phase 3 trial for CCH could position it as a leader in addressing this gap, provided regulatory and clinical hurdles are overcome. The broader industry trend of leveraging real-world evidence to guide treatment decisions underscores the strategic importance of Keenova's data-driven approach.
What we're watching
- Regulatory Pathway
- Whether Keenova can secure FDA approval for CCH as a nonsurgical treatment for plantar fibromatosis, given its current lack of approval for this indication.
- Clinical Trial Progress
- The pace at which Keenova's Phase 3 clinical trial for CCH in plantar fibromatosis advances and whether it meets primary endpoints.
- Market Opportunity
- How the real-world evidence on treatment patterns influences the adoption of potential new therapies for plantar fibromatosis.